# FDA Approves Label Supplement for iDose TR

Page: https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/fda-approves-label-supplement-for-idose-tr
Text version: https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/fda-approves-label-supplement-for-idose-tr.md
Podcast: [Eyewire News: The Podcast](https://stenobird.com/podcast/eyewire-news-the-podcast-7055536)
Published: 2026-01-28T20:00:00+00:00
Episode link: https://traffic.megaphone.fm/BMCL6362351584.mp3
Audio file: https://traffic.megaphone.fm/BMCL6362351584.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/fda-approves-label-supplement-for-idose-tr
Duration seconds: 337

## Resource

The FDA approves a key label supplement for Glaukos’ iDoseTR; Nidek announces the European launch of a new open-field refraction system; and there have been several leadership changes announced during the first month of 2026. Learn more about your ad choices. Visit megaphone.fm/adchoices

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/fda-approves-label-supplement-for-idose-tr/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/fda-approves-label-supplement-for-idose-tr.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.